FDA Grants Rare Pediatric Disease Designation to Achondroplasia Drug

On March 11, the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to ABSK061, a drug developed by Abbisko Therapeutics for the treatment of achondroplasia. Achondroplasia is a rare genetic condition that affects bone growth and is associated with mutations in the FGFR3 gene (know more about achondroplasia here).

The FDA’s Rare Pediatric Disease designation program aims to encourage the development of treatments for serious and rare conditions that primarily affect children and adolescents. This designation provides regulatory and financial incentives and may help accelerate the evaluation of future medicines.

About the treatment

ABSK061 is a selective inhibitor of FGFR2 and FGFR3 proteins, developed for oral administration in capsule form. Its mechanism targets pathways involved in abnormal bone growth in achondroplasia.

Clinical development

According to available information, a Phase 2 clinical trial is being prepared in children aged 3 to 12 years with achondroplasia. All clinical trial sites are located in China.

Preclinical data indicate activity on the intended target, along with a pharmacokinetic and safety profile considered promising. Its oral administration may represent a more convenient option, particularly for children.

Significance for the field

The development of new therapeutic approaches represents an important step forward in achondroplasia research. However, potential approval, availability, and clinical impact will depend on the results of ongoing studies and regulatory evaluation processes.

Regulatory status

The granting of Rare Pediatric Disease designation does not constitute marketing authorization. ABSK061 remains under development, study, and clinical evaluation, and additional data are required to confirm its efficacy and safety.

Situation in Europe

In Europe, ABSK061 has not yet been submitted for evaluation by regulatory authorities.

Any future application for marketing authorization will need to be assessed by the European Medicines Agency (EMA). If approved, each European country will subsequently decide on access and reimbursement pathways, which typically occur after central authorization.